TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8880057

Group type: EXPERIMENTAL
Intervention: Orlistat 50 mg 3 times daily for 7 or 8 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Orlistat with furosemide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Orlistat with nifedipine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Orlistat with captopril
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Orlistat with atenolol
Number of subjects: 8
Study: 1710919

Group type: EXPERIMENTAL
Intervention: COP-BLAM/IMVP-16 protocol
Number of subjects: 548

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 548
Study: 6150771

Group type: EXPERIMENTAL
Intervention: Insulin plus saline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Insulin plus cimetidine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Insulin plus dextrose
Number of subjects: 6
Study: 30219887

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 640

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 640
Study: 31803504

Group type: EXPERIMENTAL
Intervention: EGFR inhibitors (cetuximab or panitumumab) plus oxaliplatin or irinotecan-based chemotherapy
Number of subjects: 261
Study: 28806430

Group type: EXPERIMENTAL
Intervention: Conventional technique (6 clinical sessions)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Abbreviated technique (3 clinical sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline with old dentures
Number of subjects: 20
Study: 26159137

Group type: EXPERIMENTAL
Intervention: Incontinence Care Protocol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional skin care
Number of subjects: 120
Study: 24195949

Group type: EXPERIMENTAL
Intervention: Intrathecal SP‐SAP (20‐60 ?g) in addition to standard‐of‐care analgesic therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard‐of‐care analgesic therapy alone (control)
Number of subjects: 70
Study: 21626017

Group type: EXPERIMENTAL
Intervention: LED therapy (GaAlAs, 640 nm, 4 J/cm(2), 0.10 W, 70 s)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Laser therapy (InGaAlP, 660 nm, 4 J/cm(2), 0.03 W, 25 s)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 18633599

Group type: EXPERIMENTAL
Intervention: Polidocanol 5 mg/ml (group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Polidocanol 10 mg/ml (group B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Polidocanol 10 mg/ml (additional treatment for unsatisfied patients)
Number of subjects: 52
Study: 16418023

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg intravenously
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Meperidine 0.4 mg/kg intravenously
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 75
Study: 14508404

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tracheal suctioning
Number of subjects: 6
Study: 10828671

Group type: EXPERIMENTAL
Intervention: Propiverine (15 mg t.i.d.)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (t.i.d.)
Number of subjects: 98
Study: 9126713

Group type: EXPERIMENTAL
Intervention: Cognitive-existential group therapy integrated over 6 months with adjuvant chemotherapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-existential group therapy
Number of subjects: 0
Study: 8095119

Group type: EXPERIMENTAL
Intervention: mezlocillin intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: not treated with mezlocillin (control)
Number of subjects: 0
Study: 2876741

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (250 micrograms/h continuously during 120 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cimetidine (200 mg IV every 4 h for 5 days) and pirenzepine (10 mg IV every 8 h for 5 days)
Number of subjects: 60
Study: 31602530

Group type: EXPERIMENTAL
Intervention: Islet transplantation (IT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Thresholds for diagnosing IT success at 6 months post-transplant: SD at 22.76 mg/dL (sensitivity 88.89%, specificity 80.00%); CV at 17.47% (sensitivity 88.89%, specificity 70.00%); MAGE at 54.81 mg/dL (sensitivity 88.89%, specificity 80.00%); GVP at 12.27% (sensitivity 88.89%, specificity 70.00%).
Number of subjects: 29
Study: 29422651

Group type: EXPERIMENTAL
Intervention: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach for 75g carbohydrate meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach for 45g carbohydrate meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overestimated meal insulin bolus for 75g carbohydrate meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overestimated meal insulin bolus for 45g carbohydrate meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach
Number of subjects: 20
Study: 26210058

Group type: EXPERIMENTAL
Intervention: Active DLPFC stimulation (bipolar-balanced montage)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham DLPFC stimulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Active DLPFC stimulation (bipolar-unbalanced montage)
Number of subjects: 60
Study: 24898426

Group type: EXPERIMENTAL
Intervention: Estimated femoral strength from finite element analysis of DXA scans
Number of subjects: 7860

Group type: COMPARATOR
Intervention: Total hip BMD
Number of subjects: 7860

Group type: COMPARATOR
Intervention: Femoral neck (FN) BMD
Number of subjects: 7860

Group type: COMPARATOR
Intervention: FRAX scores
Number of subjects: 7860

Group type: COMPARATOR
Intervention: Hip structure analysis (HSA) variables
Number of subjects: 7860

Group type: EXPERIMENTAL
Intervention: Estimated femoral strength
Number of subjects: 7860
Study: 22903395

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus zoledronic acid
Number of subjects: 294

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 294
Study: 20406425

Group type: EXPERIMENTAL
Intervention: Maternal report of any signs of neonatal illness
Number of subjects: 16059

Group type: COMPARATOR
Intervention: Community health workers (CHWs) assessment of neonatal illness
Number of subjects: 16059
Study: 18690349

Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) administration for four consecutive days after thermal injury
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-antithrombin (non-AT) treatment
Number of subjects: 31
Study: 15978306

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus HCTZ 12.5 mg OD
Number of subjects: 1079

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus HCTZ 25 mg OD
Number of subjects: 1079

Group type: COMPARATOR
Intervention: Amlodipine 10 mg OD
Number of subjects: 1079
Study: 12633189

Group type: COMPARATOR
Intervention: Soap and water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorine-containing towels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waterless rub containing 61% ethyl alcohol
Number of subjects: 0
Study: 10500023

Group type: EXPERIMENTAL
Intervention: Black currant seed oil (BCSO) supplementation for 2 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (soybean oil)
Number of subjects: 40
Study: 8992964

Group type: EXPERIMENTAL
Intervention: 125 mg paracetamol suppository
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 250 mg paracetamol suppository
Number of subjects: 18

Group type: COMPARATOR
Intervention: 500 mg cut-in-half paracetamol tablet
Number of subjects: 18
Study: 1881721

Group type: EXPERIMENTAL
Intervention: Postpartum visit with primary care provider and telephone access
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (no postpartum visit)
Number of subjects: 251
Study: 6104935

Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg orally at 2200 h and 0800 h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diazepam 10 mg orally at the same times
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg orally
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diazepam 10 mg orally
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 50
Study: 30695075

Group type: EXPERIMENTAL
Intervention: Upfront point-of-care testing
Number of subjects: 0
Study: 28777756

Group type: EXPERIMENTAL
Intervention: Safinamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26414562

Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass surgery with minimal gastric resection (DJBm)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 17
Study: 23419665

Group type: EXPERIMENTAL
Intervention: Physical masking ODT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gustatory masking ODT
Number of subjects: 0
Study: 17940025

Group type: EXPERIMENTAL
Intervention: 5 days of integrative body‐mind training (20 minutes per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 40
Study: 15497662

Group type: EXPERIMENTAL
Intervention: Test formulation (Kolestor)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 24
Study: 10886610

Group type: EXPERIMENTAL
Intervention: Wheat bread diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rye bread diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 9481974

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam intravenously
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam rectally
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 35 mg diazepam rectally
Number of subjects: 24
Study: 7913572

Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sulpiride
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bromperidol and Sulpiride
Number of subjects: 45
Study: 3525029

Group type: EXPERIMENTAL
Intervention: TCDO (Oxoferin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Beta-isodona
Number of subjects: 60
Study: 30171452

Group type: EXPERIMENTAL
Intervention: Culturally-tailored counseling center for PrEP
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 50
Study: 30184543

Group type: EXPERIMENTAL
Intervention: Biweekly cetuximab (500 mg/m2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Weekly cetuximab (250 mg/m2)
Number of subjects: 36
Study: 26917072

Group type: COMPARATOR
Intervention: Contact Lens (CL)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Intraocular Lens (IOL)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cataract surgery before 49 days of age
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cataract surgery after 49 days of age
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Orthotropia or microtropia (<10(Δ))
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Strabismus (≥10(Δ))
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Orthotropia
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Strabismus
Number of subjects: 112
Study: 22809163

Group type: EXPERIMENTAL
Intervention: Enhanced patient participation (EPP)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard treatment protocol (TP)
Number of subjects: 210
Study: 22276821

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m² on day 1)
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m² on day 1) + Capecitabine (825 mg/m² twice a day on days 1 to 14)
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m² on day 1) + Gemcitabine (1000 mg/m² on days 1 and 8)
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg for the first six cycles of chemotherapy)
Number of subjects: 1206

Group type: COMPARATOR
Intervention: No Bevacizumab
Number of subjects: 1206
Study: 20858863

Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Killip class (class 3 or 4 versus 1 or 2)
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Heart rate (>70 beats per minute)
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Creatinine (>90 μmol/L)
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Sum of ST‐segment deviations
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Anterior STEMI location
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: C-index
Number of subjects: 5745
Study: 17974528

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15848695

Group type: EXPERIMENTAL
Intervention: Thymoglobulin, sirolimus, reduced-dose cyclosporine, and corticosteroids
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Immune-monitoring study
Number of subjects: 36
Study: 12088164

Group type: EXPERIMENTAL
Intervention: Ziprasidone, 80-160 mg/day (N = 148)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Haloperidol, 5-15 mg/day (N = 153)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 301

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Ziprasidone and Haloperidol
Number of subjects: 301
Study: 10206381

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (moderate and heavy smokers)
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1592
Study: 7607914

Group type: EXPERIMENTAL
Intervention: Intraoperative facial nerve monitoring using two different two-channel electromyography units
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (24 patients without monitoring)
Number of subjects: 35
Study: 2221488

Group type: EXPERIMENTAL
Intervention: Quazolast, 400 mg bid orally
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 74533

Group type: EXPERIMENTAL
Intervention: Concentrated dietary fibre from bran (20 g/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Concentrated dietary fibre from cabbage (20 g/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Concentrated dietary fibre from carrot (20 g/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Concentrated dietary fibre from apple (20 g/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Concentrated dietary fibre from guar gum (20 g/day)
Number of subjects: 19
Study: 31887280

Group type: EXPERIMENTAL
Intervention: Grid pattern
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Sextant pattern
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Quadrant pattern
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: All 3 patterns
Number of subjects: 661
Study: 30457436

Group type: EXPERIMENTAL
Intervention: HDC vaccine (HDCV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hamster kidney cell vaccine
Number of subjects: 100
Study: 28482991

Group type: EXPERIMENTAL
Intervention: Warm showers (40 °C to 43 °C for approximately 20 minutes)
Number of subjects: 358

Group type: COMPARATOR
Intervention: No warm showers (control group)
Number of subjects: 358
Study: 25823791

Group type: EXPERIMENTAL
Intervention: T-pouch ileal orthotopic neobladder
Number of subjects: 484

Group type: COMPARATOR
Intervention: Studer ileal orthotopic neobladder
Number of subjects: 484
Study: 23651537

Group type: EXPERIMENTAL
Intervention: Primary Care Triple P (n = 34)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Wait-list control group (n = 33)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Secondary measurements
Number of subjects: 67
Study: 21338892

Group type: EXPERIMENTAL
Intervention: Random laboratory drug testing program (PDT)
Number of subjects: 114
Study: 19149760

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy or EGFR inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New EGFR inhibitors
Number of subjects: 0
Study: 17418721

Group type: EXPERIMENTAL
Intervention: Argon laser (10 seconds)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional curing light (40 seconds)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 23
Study: 15202617

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 11229673

Group type: EXPERIMENTAL
Intervention: Intratumoral injection of HSV1716 (10^3 plaque-forming units)
Number of subjects: 5
Study: 9745056

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lichtenstein mesh repair
Number of subjects: 40
Study: 8156069

Group type: EXPERIMENTAL
Intervention: Passive SLR with opposite hip extended
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Active SLR with opposite hip extended
Number of subjects: 22

Group type: COMPARATOR
Intervention: Trial 1
Number of subjects: 22

Group type: COMPARATOR
Intervention: Trial 2
Number of subjects: 22
Study: 3340661

Group type: EXPERIMENTAL
Intervention: He‐Ne laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29617081

Group type: EXPERIMENTAL
Intervention: Monopolar TURBT (M‐TURBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bipolar TURBT (B‐TURBT)
Number of subjects: 90
Study: 26335185

Group type: EXPERIMENTAL
Intervention: PCOS group 1 (oligomenorrhea/anovulation and hyperandrogenemia/hyperandrogenism)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PCOS group 2 (anovulation and polycystic ovaries)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PCOS group 3 (hyperandrogenemia and polycystic ovaries)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PCOS group 4 (anovulation, hyperandrogenemia and polycystic ovaries)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (age- and weight-matched healthy controls)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: All PCOS groups
Number of subjects: 89
Study: 25638740

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 1.2mcg/kg/hour (high dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.4mcg/kg/hour (low dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23589673

Group type: EXPERIMENTAL
Intervention: vinblastine + prednisone + methotrexate (Arm B)
Number of subjects: 400

Group type: COMPARATOR
Intervention: vinblastine + prednisone (Arm A)
Number of subjects: 400

Group type: COMPARATOR
Intervention: vinblastine + prednisone (Arm C, 6 months)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: vinblastine + prednisone (Arm D, 12 months)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Historical controls (LCH-I, 6 months)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Historical controls (LCH-II, 6 months)
Number of subjects: 400
Study: 21180239

Group type: EXPERIMENTAL
Intervention: Acute exercise (maximal symptom limited exercise stress testing on cycloergometer)
Number of subjects: 79
Study: 19138934

Group type: EXPERIMENTAL
Intervention: Intervention group (smokers with oral tissue methylation)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (smokers without oral tissue methylation)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Baseline methylation for p16 in bronchial tissue
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Baseline methylation for FHIT in bronchial tissue
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Baseline methylation for both p16 and FHIT in bronchial tissue
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Baseline methylation for p16 in oral tissue
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Baseline methylation for FHIT in oral tissue
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Baseline methylation for both p16 and FHIT in oral tissue
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Correlation of methylation patterns between oral and bronchial tissues
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 3 months after intervention
Number of subjects: 127
Study: 16816304

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 336
Study: 12799402

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/d)
Number of subjects: 1809

Group type: COMPARATOR
Intervention: Aspirin (650 mg/d)
Number of subjects: 1809
Study: 11795342

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day) for up to 8 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 0
Study: 9175685

Group type: EXPERIMENTAL
Intervention: Umbilical artery pulsatility index
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Umbilical venous flow velocity
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fetal aortic volume flow
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oligohydramnios
Number of subjects: 44

Group type: COMPARATOR
Intervention: Birth asphyxia
Number of subjects: 44

Group type: COMPARATOR
Intervention: Uterine flow
Number of subjects: 44
Study: 1415419

Group type: EXPERIMENTAL
Intervention: Nifedipine and bed rest
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bed rest alone
Number of subjects: 200
Study: 3002135

Group type: EXPERIMENTAL
Intervention: doxorubicin‐cyclophosphamide (DC)
Number of subjects: 102

Group type: COMPARATOR
Intervention: cyclophosphamide‐methotrexate‐5‐fluorouracil‐vincristine‐prednisone (CMFVP)
Number of subjects: 102
Study: 31917424

Group type: EXPERIMENTAL
Intervention: Low recurrence score (n=121)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Intermediate or high recurrence score (n=195)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Mastectomy without radiotherapy, low recurrence score (n=unknown)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Mastectomy without radiotherapy, intermediate or high recurrence score (n=unknown)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Subset analysis, low recurrence score (n=unknown)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Subset analysis, intermediate or high recurrence score (n=unknown)
Number of subjects: 316